Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04115761 | Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients | recruiting | Phase 2 | 24 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06558214 | OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial(OPTIMUS PRIME) | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | recruiting | Phase 2 | 52 | Inova Health Care ServicesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06816927 | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab(GIANT) | recruiting | Phase 2 | 92 | Duke UniversityOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT05052957 | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)(hSTAR GBM) | recruiting | Phase 2 | 16 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06894225 | Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature | recruiting | Phase 2 | 12 | National Neuroscience InstituteOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07356973 | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma(OPTICAL) | recruiting | Phase 2 | 147 | CRISM Therapeutics LTDINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | recruiting | Phase 2 | 256 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT02977780 | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | recruiting | Phase 2 | 460 | David Reardon, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06319027 | Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial(GABLE) | recruiting | Phase 2 | 100 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | recruiting | Phase 1 / Phase 2 | 40 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07003542 | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas | recruiting | Phase 2 | 48 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05708352 | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | recruiting | Phase 2 | 170 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)(BORTEM-17) | recruiting | Phase 1 / Phase 2 | 63 | Haukeland University HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06069726 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial(MOAB) | recruiting | Phase 2 | 80 | Duke UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | recruiting | Phase 1 / Phase 2 | 55 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 190 | Baptist Health South FloridaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05879250 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 39 | Northwestern UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06177964 | Lerapolturev (PVSRIPO) in GBM | recruiting | Phase 2 | 92 | Darell BignerOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07225621 | Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 103 | Alpheus Medical, Inc.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04623931 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06805305 | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | recruiting | Phase 2 | 180 | Diakonos Oncology CorporationINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07284628 | Vortioxetine for Newly Diagnosed Glioblastoma(ReVoGlio) | recruiting | Phase 2 | 78 | University of ZurichOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07670026 | Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression | recruiting | Phase 2 | 31 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | recruiting | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05590689 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor(ALA-RDTinGBM) | recruiting | Phase 1 / Phase 2 | 34 | Universität MünsterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07392957 | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT06622434 | New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study(NAVIG-1) | recruiting | Phase 1 / Phase 2 | 35 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07037004 | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06011109 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | recruiting | Phase 1 / Phase 2 | 30 | Aveta Biomics, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials